The uptick in Parkinson's disease (PD) programs that began in the first half of this decade is accelerating across the span of drug development, leading to a recent approval, multiple candidates in late-stage development and M&A in the space. Although disease-modifying therapies – the Holy Grail of PD treatment – may be years or perhaps decades away, more effective forms of levodopa (L-dopa) treatment now are augmented by drugs designed to manage nonmotor symptoms.